New cocktail of smart drugs aims to wipe out leukemia with less poison
NCT ID NCT07643103
First seen Jun 18, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new approach for adults newly diagnosed with a type of leukemia called Ph-negative B-ALL. Instead of standard high-dose chemo, patients get a mix of low-dose chemo plus several targeted drugs (Inotuzumab, Venetoclax, Blinatumomab) and possibly CAR-T cell therapy. The goal is to see if this combination can clear the cancer more deeply and safely. The study plans to enroll 32 people and will track how many achieve a complete remission with no detectable cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PH- ACUTE LYMPHOBLASTIC LEUKEMIA (PH-ALL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inotuzumab Ozogamicin, Venetoclax, Blinatumomab, and CD19 CAR-T cells
What this could lead to
If successful, this could offer a more effective and less toxic first treatment for a type of leukemia, potentially reducing the need for intensive chemotherapy.
What could go wrong
This is a small, early-phase trial (32 people) with no control group, so results may not apply broadly. The drug combination also carries risks of serious side effects like infections or organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.